The Healthcare Problem We Solve
There is a significant unmet medical need to generate better outcomes for sufferers of respiratory infections.
Increasing numbers of people are being put at risk by viruses, many of them by new and mutating viruses, which are emerging globally at an accelerating rate.
Current vaccines and treatments have limited impact but Respana Therapeutics has the ability to address this pressing unmet need with a novel monoclonal antibody, RT-002.
RT-002 targets the patient’s immune response to the infection, not the infectious agent itself, and has the potential to be first-in-class with several large-market therapeutic opportunities.